悦康药业：YKYY018雾化吸入剂获FDA临床试验批准

Core Viewpoint - Yuyuan Pharmaceutical's subsidiary has received FDA approval for clinical trials of YKYY018, a novel aerosol inhalation drug aimed at preventing and treating respiratory syncytial virus (RSV) infections, addressing a significant unmet medical need in the market [1] Company Summary - Yuyuan Pharmaceutical's subsidiary, Beijing Yuyuan Kecai Pharmaceutical Technology Co., Ltd., has developed YKYY018, an original membrane fusion inhibitor drug utilizing a full-process AI platform [1] - The drug is positioned to fill a gap in the market as there are currently no approved treatments for RSV infections globally [1] Industry Summary - The clinical treatment field for RSV infections shows a significant and urgent unmet demand, highlighting the potential market opportunity for new therapeutic options [1]